Luis Lara-Mejía, Medical Oncologist Specialized in Thoracic Neoplasms at National Institute of Cancerology, posted on X:

“Proud to share our new publication in Nature Communications, led by Oscar Arrieta and an extraordinary team effort.

Alectinib + bevacizumab as 1L therapy in metastatic ALK+ NSCLC:

ORR: 100%
12 and 36 month PFS: 97% and 64.2%
36-month intracranial PFS: 87.8%
While not practice-changing yet, this phase II trial lays a solid foundation to explore antiangiogenic combinations in ALK+ NSCLC, especially in patients with poorer prognosis.
Even in the lorlatinib era, early resistance remains a challenge.

Could combinations help us shift the curve earlier? Let’s keep asking. Let’s keep pushing.”

Title: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial

Authors: Oscar Arrieta, Luis Lara-Mejía, Eduardo Rios-Garcia, Enrique Caballé-Perez, Luis Cabrera-Miranda, Maritza Ramos-Ramírez, David Dávila-Dupont, Andrés F. Cardona, Graciela Cruz-Rico, Jordi Remon, Alexandra Garcilazo-Reyes, Rafael Rosell

Read The Article at Nature Communications.

Luis Lara-Mejía: Early Resistance in ALK+ NSCLC Targeted with Alectinib and Bevacizumab Combo